<DOC>
	<DOCNO>NCT00095264</DOCNO>
	<brief_summary>The purpose study assess effect 13 week darbepoetin alfa treatment erythroid response anemic subject low risk Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>A Study Darbepoetin Alfa Anemic Subjects With Low Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Eligibility Criteria : General : Low risk MDS ( low intermediate1 risk define IPSS ) FAB classification RA , RARS , RAEB blast less equal 10 % determined via bone marrow biopsy CBC Adequate iron store determine bone marrow film section stain iron via bone marrow biopsy ECOG Performance status score 0 , 1 , 2 Laboratory : Local laboratory screen Hgb le equal 11.0g/dL Adequate renal function ( serum creatinine concentration less equal 2.0 mg/dL ) Adequate liver function ( total bilirubin less equal 2 time , ALT le equal 3 time , AST le equal 3 time upper limit respective normal range ) Ethical : Must 18 year age old Provide write Institutional Review Board ( IRB ) approve informed consent screening procedure perform</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>